NNV-019

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameNNV-019

Drug Alias NameCD37-targeting antibody-drug conjugate (Nordic Nanovector)CD37-targeting antibody-drug conjugate (LegoChem Biosciences/Nordic Nanovector)NNV-019

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionLeukocyte antigen CD37 modulators

TargetsLeukocyte antigen CD37

Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNorwaySouth Korea

CombinationsNo

Global Highest StatusSuspended

Highest Status in ChinaN/A

Originator CompaniesNordic Nanovector Asa

China Registration ClassN/A

Develop Information

Active CompaniesNordic Nanovector Asa

Inactive CompaniesLigaChem Biosciences Inc

Active IndicationsLymphoma, Non-HodgkinLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A